Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Molecularly characterising triple negative breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.05.12
Views: 3896
Rating:

Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium

Prof Jorge Reis-Filho talks to ecancer about molecularly characterising triple negative breast cancer at IMPAKT 2012 in Brussels, May 2012.

 

At the molecular level, triple negative breast cancer is not a single disease. There are a larger number of heterogeneous tumours, which means that this disease cannot be analysed in the same way as other types of breast cancer.

 

The differences between diseases are the biological starting point for testing different therapeutic agents against triple negative breast cancer. The different subtypes of tumours can each respond differently to strategies, but will give prognostic signatures that will point to a quick and clear prognosis. However, there are complications with what type of prognostic signatures can be used in triple negative cases.

 

Filming Supported by Amgen

Related videos

follow us

WIN 2019


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation